Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation

This trial is testing a combination of three treatments before surgery — camrelizumab (immunotherapy), fluzoparib (a PARP inhibitor), and nab-paclitaxel (chemotherapy) — in people with early-stage breast cancer that carries mutations in DNA repair genes (called HRR genes). These mutations may make the cancer more responsive to PARP inhibitors. **You may be eligible if...** - You have HER2-negative early-stage breast cancer (specific stages T1c N1-2, T2-4 N0-2, or any T with N3) - Your cancer carries a mutation in BRCA1, BRCA2, PALB2, ATM, or other HRR genes - You have not received prior breast cancer treatment - Your general health is good (ECOG 0–1) and cancer has not spread to distant organs **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have had another cancer in the past 2 years - You have autoimmune disease requiring treatment or a history of serious immune-related complications - You have significant heart problems Talk to your doctor to see if this trial is right for you.